Cargando…

Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib

BACKGROUND: Imatinib is a long-term, oral, targeted therapy for high-risk resected and advanced gastrointestinal stromal tumours (GIST). It is known that sarcopenia affects prognosis and treatment tolerance in patients with various solid cancers. We analysed lumbar skeletal muscle index changes in i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moryoussef, Frédérick, Dhooge, Marion, Volet, Julien, Barbe, Coralie, Brezault, Catherine, Hoeffel, Christine, Coriat, Romain, Bouché, Olivier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670743/ https://www.ncbi.nlm.nih.gov/pubmed/26673372 http://dx.doi.org/10.1002/jcsm.12047

Ejemplares similares

Impact of Sarcopenia on Survival in Patients Treated with FOLFIRINOX in a First-Line Setting for Metastatic Pancreatic Carcinoma
por: Lellouche, Lisa, et al.
Publicado: (2023)

Anti-epidermal or anti-vascular endothelial growth factor as first-line metastatic colorectal cancer in modified Glasgow prognostic score 2' patients
por: Dréanic, Johann, et al.
Publicado: (2015)

Medical Treatment of Advanced Pancreatic Neuroendocrine Neoplasms
por: Palmieri, Lola-Jade, et al.
Publicado: (2020)

Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review
por: Falette Puisieux, Manon, et al.
Publicado: (2022)

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
por: Joensuu, Heikki, et al.
Publicado: (2017)

Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy
por: Mortier, Victor, et al.
Publicado: (2022)

Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
por: Rémond, M.S., et al.
Publicado: (2022)

EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib
por: Bouché, Olivier, et al.
Publicado: (2018)

Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010)

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008)

Optimizing Adherence to Adjuvant Imatinib in Gastrointestinal Stromal Tumor
por: Tetzlaff, Eric D., et al.
Publicado: (2013)

Update on imatinib for gastrointestinal stromal tumors: duration of treatment
por: Linch, Mark, et al.
Publicado: (2013)

Overcoming heterogenity in imatinib-resistant gastrointestinal stromal tumor
por: Serrano, César, et al.
Publicado: (2019)

Self-expandable metal stent through the tumor to treat an intestinal obstruction due to pancreatic squamous cell carcinoma
por: Soliman, Heithem, et al.
Publicado: (2017)

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
por: Sawaki, Akira, et al.
Publicado: (2014)

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018)

Imatinib in gastrointestinal stromal tumour: Northern Cancer Network experience
por: Azribi, F, et al.
Publicado: (2009)

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
por: Quek, Richard, et al.
Publicado: (2010)

ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor
por: Rink, Lori, et al.
Publicado: (2013)

Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors
por: Sicklick, Jason K., et al.
Publicado: (2013)

Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors
por: Takahashi, Tsuyoshi, et al.
Publicado: (2017)

Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor
por: Huang, Wen-Kuan, et al.
Publicado: (2020)

Gastrointestinal Stromal Tumor With Chondrosarcomatous Dedifferentiation Following Imatinib Therapy
por: Koufopoulos, Nektarios, et al.
Publicado: (2021)

Imatinib-induced podocytopathies in a patient with gastrointestinal stromal tumor
por: Wang, Gang, et al.
Publicado: (2021)

Identification of Novel Imatinib-Resistant Genes in Gastrointestinal Stromal Tumors
por: Cao, Lei, et al.
Publicado: (2022)

A narrative review of imatinib-resistant gastrointestinal stromal tumors
por: Hayashi, Yujiro, et al.
Publicado: (2021)

Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective
por: Date, Ravindra S, et al.
Publicado: (2008)

Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy
por: Annaberdyev, Shohrat, et al.
Publicado: (2009)

Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
por: Gauden, Ruth, et al.
Publicado: (2011)

Complete pathological response to Imatinib mesylate in an extraintestinal gastrointestinal stromal tumor
por: Quezada, Nicolás, et al.
Publicado: (2014)

Rhabdomyosarcomatous Transformation of a Gastrointestinal Stromal Tumor following Treatment with Imatinib
por: Jiang, Xiaoyin, et al.
Publicado: (2015)

Imatinib-induced Ototoxicity in a Patient with Gastrointestinal Stromal Tumor (GIST)
por: Wasif, Komal, et al.
Publicado: (2016)

Disappearing pigmentary mosaicism during imatinib treatment for gastrointestinal stromal tumors
por: Coleman, Emily, et al.
Publicado: (2019)

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
por: Tang, Sumin, et al.
Publicado: (2017)

Recent Advancements in the Treatment of Rectal Gastrointestinal Stromal Tumor: In Era of Imatinib
por: Qu, Hui, et al.
Publicado: (2022)

Advances in the research of the mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors
por: Hu, Xiangchen, et al.
Publicado: (2022)

Neoadjuvant versus adjuvant imatinib in primary localized gastrointestinal stromal tumor
por: Ling, Jiayu, et al.
Publicado: (2023)

Measuring Tumour Imatinib Concentrations in Gastrointestinal Stromal Tumours: Relevant or Redundant?
por: Giraud, Eline L., et al.
Publicado: (2023)

Imatinib Plasma Monitoring-Guided Dose Modification for Managing Imatinib-Related Toxicities in Gastrointestinal Stromal Tumor Patients
por: Yoon, Shinkyo, et al.
Publicado: (2013)

Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
por: Katsumata, Ryo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_et8gcu2kre27ehecqqlrav691p